Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 5/20 | 0.70 |
| ▸ | XDH | P47989 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403692 | 0.79 | FEN1 (0.66) | MPOXDHALDH1A1DAOFEN1 | |
| SCHEMBL6668697 | 0.74 | CA9 (0.59) | MPOXDHALDH1A1DAOFEN1 | |
| SCHEMBL4506198 | 0.73 | ALDH1A1 (0.61) | ALDH1A1GAAFEN1KDM4EGLA | |
| SCHEMBL6400493 | 0.73 | CA12 (0.68) | MPOXDHALDH1A1GAAFEN1 | |
| SCHEMBL328468 | 0.73 | KDM4E (0.49) | MPOXDHALDH1A1DAOGAA | |
| SCHEMBL6401713 | 0.71 | ALDH1A1 (0.59) | MPOALDH1A1GAAFEN1KDM4E | |
| SCHEMBL6401721 | 0.71 | CA9 (0.66) | MPOALDH1A1DAOGAAKDM4E | |
| SCHEMBL10085593 | 0.71 | ALDH1A1 (0.72) | MPOALDH1A1DAOGAAKDM4E | |
| SCHEMBL6406738 | 0.71 | CA9 (0.66) | ALDH1A1KDM4EMEN1KMT2ACA12 | |
| SCHEMBL7653637 | 0.69 | MPO (0.43) | MPOXDHALDH1A1DAOFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | MPO 2232/4885XDH 1508/4885ALDH1A1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.